Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 4/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.30 |
| ▸ | NQO2 | P16083 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21899872 | 0.86 | CYP11B1 (0.35) | CYP11B2CYP11B1AHRKDM4EMEN1 | |
| SCHEMBL30579319 | 0.84 | CYP11B2 (0.36) | CYP11B2CYP11B1CYP17A1CYP3A4AHR | |
| SCHEMBL21855501 | 0.84 | AHR (0.35) | CYP11B2CYP11B1CYP17A1CYP3A4AHR | |
| SCHEMBL20542249 | 0.84 | CYP11B2 (0.36) | CYP11B2CYP11B1CYP17A1CYP3A4AHR | |
| SCHEMBL20557960 | 0.81 | AHR (0.33) | CYP11B2CYP11B1CYP17A1CYP3A4AHR | |
| SCHEMBL20558149 | 0.81 | AHR (0.49) | CYP11B2CYP11B1CYP17A1CYP3A4AHR | |
| SCHEMBL20557838 | 0.81 | AHR (0.33) | CYP11B2CYP11B1CYP17A1CYP3A4AHR | |
| SCHEMBL30579373 | 0.81 | AHR (0.33) | CYP11B2CYP11B1CYP17A1CYP3A4AHR | |
| SCHEMBL21855459 | 0.79 | POLB (0.35) | CYP11B2CYP11B1CYP17A1CYP3A4AHR | |
| SCHEMBL21855484 | 0.76 | PIK3CA (0.39) | AHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144839-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2022-05-12 | — | — | US | disclosed |
| WO-2020081636-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144839-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | CYP11B2 86/4885CYP11B1 77/4885CYP17A1 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.